Patents.us
Patents/USRE049477

USRE049477No. USRE049477reissueGranted 3/28/2023

Claims (21)

Claim 1 (Independent)

1. A chimeric, humanized, or single-chain antibody which comprises a light chain variable region comprising complementarity determining regions comprising the amino acid sequences SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a heavy chain variable region comprising complementarity determining regions comprising the amino acid sequences SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, or a fragment of said chimeric or humanized antibody, which antibody or antibody fragment binds the C-terminal telopeptide of the α2(I) chain of human collagen I.

Claim 10 (Independent)

10. The antibody according to claim 1 3 , which is a single chain antibody.

Claim 12 (Independent)

12. The single chain antibody according to claim 11 10 , wherein the antibody further comprises a linker comprising a sequence of one or more amino acids linking said light chain variable region and said heavy chain variable region.

Claim 20 (Independent)

20. A pharmaceutical composition comprising the antibody or antibody the fragment according to claim 1 3 and a pharmaceutically acceptable carrier.

Claim 21 (Independent)

21. The chimeric, humanized, or single-chain antibody or the fragment according to claim 3, wherein the antibody or fragment each comprises the light variable region having the amino acid sequence shown in SEQ ID NO:10 and the heavy chain variable region having the amino acid sequence SEQ ID NO:11.

Show 16 dependent claims
Claim 2 (depends on 1)

2. The antibody or antibody fragment according to claim 1 , which is a chimeric antibody or fragment of a chimeric antibody, which fragment binds the C-terminal telopeptide of the α2(I) chain of human collagen.

Claim 3 (depends on 2)

3. The A chimeric , humanized, or single-chain antibody according to claim 2 , which comprises comprising an antibody light chain comprising three complementarity determining regions of a light variable region having the amino acid sequence shown in SEQ ID NO:10, and an antibody heavy chain comprising three complementarity determining regions of a heavy chain variable region having the amino acid sequence SEQ ID NO:11, or a fragment of said chimeric antibody which , wherein the antibody or the fragment each binds the C-terminal telopeptide of the α2(I) chain of human collagen I .

Claim 4 (depends on 3)

4. The chimeric , humanized, or single-chain antibody or the fragment according to claim 3 , wherein said antibody light chain comprises a human antibody light chain constant region, and said antibody heavy chain comprises a human antibody heavy chain constant region , or a fragment of said chimeric antibody which binds the C-terminal telopeptide of the α2(I) chain of human collagen .

Claim 5 (depends on 4)

5. The chimeric , humanized, or single-chain antibody according to claim 4 , wherein the human constant regions comprise IgG constant regions.

Claim 6 (depends on 1)

6. The antibody or antibody fragment according to claim 1 , which is a humanized antibody or fragment of a humanized antibody, which fragment binds the C-terminal telopeptide of the α2(I) chain of human collagen.

Claim 7 (depends on 6)

7. The humanized antibody according to claim 6 , which comprises a human antibody framework region and/or a human antibody constant region, or a fragment of said humanized antibody which binds the C-terminal telopeptide of the α2(I) chain of human collagen.

Claim 8 (depends on 6)

8. The humanized antibody according to claim 6 , which comprises a human antibody constant region.

Claim 9 (depends on 8)

9. The humanized antibody according to claim 8 , wherein the constant region comprises an IgG constant region.

Claim 11 (depends on 10)

11. The single chain antibody according to claim 10 , wherein the single chain antibody comprises a light chain variable region having the amino acid sequence shown in SEQ ID NO:10, and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO:11.

Claim 13 (depends on 12)

13. The single chain antibody according to claim 12 , wherein the linker comprises the amino acid sequence Gly-Gly-Ser or the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29).

Claim 14 (depends on 12)

14. The single chain antibody according to claim 12 , wherein the linker connects the carboxy terminus of said light chain variable region to the amino terminus of said heavy chain variable region.

Claim 15 (depends on 13)

15. The single chain antibody according to claim 13 , wherein the linker comprises from two to twelve repeats of the amino acid sequence Gly-Gly-Ser, or from two to twelve repeats of the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29).

Claim 16 (depends on 15)

16. The single chain antibody according to claim 15 , comprising the amino acid sequence shown in SEQ ID NO:12.

Claim 17 (depends on 12)

17. The single chain antibody according to claim 12 , wherein the linker connects the carboxy terminus of said heavy chain variable region to the amino terminus of said light chain variable region.

Claim 18 (depends on 17)

18. The single chain antibody according to claim 17 , wherein the linker comprises from two to twelve repeats of the amino acid sequence Gly-Gly-Ser, or from two to twelve repeats of the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29).

Claim 19 (depends on 18)

19. The single chain antibody according to claim 18 , comprising the amino acid sequence shown in SEQ ID NO:16.

Full Description

No description text available for this patent.

Citations

This patent cites (28)

  • US3876763
  • US4316464
  • US4751079
  • US4752475
  • US5397569
  • US5530101
  • US5656439
  • US5674495
  • US5800815
  • US5925347
  • US6204367
  • US6642007
  • US6660481
  • US7365167
  • US7390885
  • US7566770
  • US9777055
  • US10973898
  • US20020104485
  • US20050136428
  • US20070077199
  • US20080050388
  • US20080131912
  • US20090104215
  • US20090203037
  • US20090252729
  • US20110044896
  • US9625951